Evidence map›Paper›PMID 40785058›Full record

ArticleCancer biology & therapy2025

Functional validation of somatic variability in

Al Obeed Allah Mohammad, Ali Esraa, Krus Ivona, Holý Petr, Haničinec Vojtěch, Ambrozkiewicz Filip, Rob Lukáš, Hruda Martin, Mrhalová Marcela, Kopečková Kateřina and 5 more

Abstract read
In one paragraph

Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Al Obeed Allah MohammadBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Ali EsraaBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Krus IvonaToxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.
Holý PetrBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Haničinec VojtěchBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Ambrozkiewicz FilipBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Rob LukášDepartment of Gynecology and Obstetrics, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic.
Hruda MartinDepartment of Gynecology and Obstetrics, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic.
Mrhalová MarcelaDepartment of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Kopečková KateřinaDepartment of Oncology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Bartáková AlenaDepartment of Gynecology and Obstetrics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
Bouda JiříDepartment of Gynecology and Obstetrics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
Spálenková AlžbětaBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Souček PavelBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.ORCID 0000-0002-4294-6799
Václavíková RadkaBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Concerning the dismal prognosis of chemoresistant patients with epithelial ovarian carcinoma (EOC), we aimed to follow up the findings of a previous whole-exome sequencing study using an orthogonal Sanger sequencing on the same patients and a separate set of 127 EOC patients (

Indexed as

Carcinoma, Ovarian EpithelialOvarian NeoplasmsPlatinumProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53AdultAgedDrug Resistance, NeoplasmFemaleHumansMiddle AgedMutationPrognosisKRAS protein, humanPlatinumProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53Epithelial ovarian carcinomaKRASplatinum sensitivityTP53transcript expressionvariant

Identifiers

PMID40785058
PMCPMC12341051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.